Merck to pay $US58m in Vioxx settlement

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.555, 2008-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The lowest-cost COX-2 inhibitor available through the US Medicare drug discount card programme is Merck's rofecoxib [Vioxx]

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 453, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Open conflict on the handling of the Merck drug Vioxx by editorial giants

By Edwards RG  

Reproductive BioMedicine Online, Vol. 13, Iss. 6, 2006-12 ,pp. : 905-905

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Merck voluntarily withdraws Vioxx worldwide due to CV risk

By  

Inpharma, Vol. 1, Iss. 1458, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

The Big Three of US Pharma: Pfizer, Merck & Co. and GlaxoSmithKline

By  

Pharmaceutical Innovation, Vol. 11, Iss. 5, 2002-08 ,pp. : 46-49

Adis International

Access to resources Recommend Favorite

Willingness versus ability to pay for drugs in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 376, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite